Clinical trials
Phase 2 Neurofibromatoses trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Indiana University | 2 |
| University of Alabama at Birmingham | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| FDA Office of Orphan Products Development | 1 |
| Kevin Kim, MD | 1 |
| Mayo Clinic | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| National Cancer Institute (NCI) | 1 |
| PTC Therapeutics | 1 |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neurofibromatoses | 12 |
| Neurofibroma, Plexiform | 7 |
| Neurofibromatosis 1 | 5 |
| Neurofibroma | 3 |
| Neurofibromatosis 2 | 3 |
| Brain Neoplasms | 1 |
| Central Nervous System Neoplasms | 1 |
| Genetic Diseases, Inborn | 1 |
| Hearing Loss | 1 |
| Hemangioblastoma | 1 |
Trials
Showing 51 to 12 of 12. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.